Particle.news
Download on the App Store
10 ARTICLES
·
2w ago

GLP-1 Drugs Linked to 45% Lower Dementia Risk in Type 2 Diabetes Patients

Two new studies strengthen evidence that medications like semaglutide may offer neuroprotective benefits, though further trials are needed to confirm broader applications.

Research indicates that diabetes drugs like Ozempic may reduce the risk of Alzheimer's by protecting brain health.
Two major studies published Monday in JAMA Neurology found that GLP-1 medications are linked to a lower risk of cognitive decline in people with Type 2 diabetes.
Image
Image

Overview

  • Researchers found that GLP-1 receptor agonists, such as semaglutide, are associated with a 45% lower risk of dementia in people with type 2 diabetes, based on a meta-analysis of 26 clinical trials involving over 160,000 participants.
  • The studies highlight that the neuroprotective effects of GLP-1 drugs may stem from their ability to reduce neuroinflammation and mitigate cardiovascular risks, beyond just controlling blood sugar levels.
  • While some observational studies suggested potential benefits of SGLT2 inhibitors for dementia prevention, placebo-controlled trials have not consistently confirmed these results.
  • Experts emphasize the need for large-scale, prospective trials to validate these findings and explore whether GLP-1 drugs could benefit non-diabetic populations at risk for dementia.
  • Ongoing clinical trials investigating semaglutide’s effects on early Alzheimer’s disease are expected to provide more definitive insights later this year.